ADMS
Adamas Pharmaceuticals, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
Market Cap: 164 Million
Primary Exchange: NASDAQ
Website: http://www.adamaspharma.com
Shares Outstanding: 27.9 Million
Float: 22.2 Million
Dividend: (%)
Beta: 1.69393837962646
Sector: Health Technology
Industry: Pharmaceuticals: Other
Ethical Flags
Longest drawdown: 522 trading days
From: 2018-01-23 To: 2020-01-17
Lowest Point:
ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.
via: Business Wire at 2019-06-10 05:00:00:000
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Adamas Pharmaceuticals, Inc. (Adamas or the Company) (Nasdaq: ADMS) directly in the Com… read more...
ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.
via: Business Wire at 2019-06-10 05:00:00:000
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Adamas Pharmaceuticals, Inc. (Adamas or the Company) (Nasdaq: ADMS) directly in the Com… read more...
ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.
via: Business Wire at 2019-06-10 05:00:00:000
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Adamas Pharmaceuticals, Inc. (Adamas or the Company) (Nasdaq: ADMS) directly in the Com… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|